Drug
Ceritinib
Data on this page refer exclusively to patients treated with
Ceritinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
ALK targeting TKI group page.
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Group | ALK targeting TKI |
| Mechanism of Action | ALK inhibitor |
| Half-life | 31-41 h |
